These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 31554817)

  • 21. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
    Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.
    Chiang NJ; Hsu C; Chen JS; Tsou HH; Shen YY; Chao Y; Chen MH; Yeh TS; Shan YS; Huang SF; Chen LT
    Sci Rep; 2016 May; 6():25369. PubMed ID: 27136744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.
    Palani M; Arunkumar R; Vanisree AJ
    Neuromolecular Med; 2014 Sep; 16(3):529-39. PubMed ID: 24840578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer.
    Dolgin E
    Nature; 2020 Nov; 587(7834):S16-S17. PubMed ID: 33208972
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G
    Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases.
    Salifu EY; Issahaku AR; Agoni C; Ibrahim MAA; Manimbulu N; Soliman MES
    Cell Biochem Biophys; 2022 Mar; 80(1):11-21. PubMed ID: 35040089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma.
    Houang M; Toon CW; Clarkson A; Sioson L; de Silva K; Watson N; Singh NR; Chou A; Gill AJ
    Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):134-8. PubMed ID: 24992173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples.
    Frankel D; Kaspi E; Roll P
    Methods Mol Biol; 2021; 2279():157-164. PubMed ID: 33683692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP; Selinger CI; Mahar A; Cooper WA
    Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FISH patterns of ROS1, MET, and ALK with a correlation of ALK immunohistochemistry in lung cancer: a case for introducing ALK immunohistochemistry 'Equivocal' interpretation category in the Ventana anti-ALK (D5F3) CDx assay - A tertiary cancer center experience.
    Singh A; Kumar R; Shetty O; Desai S; Rane S
    Indian J Cancer; 2022; 59(1):18-25. PubMed ID: 33402590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
    Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse: Results from the SJYC07 trial and institutional experience.
    Chiang J; Bagchi A; Li X; Dhanda SK; Huang J; Pinto SN; Sioson E; Dalton J; Tatevossian RG; Jia S; Partap S; Fisher PG; Bowers DC; Hassall TEG; Lu C; Zaldivar-Peraza A; Wright KD; Broniscer A; Qaddoumi I; Upadhyaya SA; Vinitsky A; Sabin ND; Orr BA; Klimo P; Boop FA; Ashford JM; Conklin HM; Onar-Thomas A; Zhou X; Ellison DW; Gajjar A; Robinson GW
    Neuro Oncol; 2024 Jan; 26(1):178-190. PubMed ID: 37503880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.